Calendar of Events
FEBRUARY 17–21, 2021
ASDIN Goes Virtual!
Interesting cases–ASDIN Unmet/High Priority Needs in Vascular Access Research. For information, please click here.
FEBRUARY 19–21, 2021
ASDIN 17th Annual Scientific Meeting
For information, please click here.
ASDIN Announces Micro Research Grants
For information, please click here.
ASDIN Accepting Applications Until December 31 for the $25K Research Grant in Vascular Access
Click here for more information.
Nephrology Practice and Dialysis
OCTOBER 30, 2020
Fresenius asks judge to reject whistleblower's demand for $11.5M in attorney fees, costs
Fresenius contends that as only one of the three allegations brought forward by a former area manager actually resulted in a settlement - albeit for far less than was originally sought - then a federal judge should reject a demand by the whistleblower for the company to pay the man $11.5 million in attorney fees and costs. Fresenius argues the suit, based upon FCA allegations that the company was billing Medicare for unnecessary hepatitis B tests, wasn't successful in any way. The U.S. Department of Justice intervened in the case and negotiated a $5.2-million settlement with Fresenius, from which the whistleblower was supposed to get a share. However, the firm calls the latest amount an exorbitant fee.
SOURCE: Law 360 (sub. req.)
To read the full article click here
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
